Browse Category:

Categories

[Search within category]

Multiplex Digital PCR

Researchers at the University of California, Irvine have developed methods to enable greater multiplexing abilities for digital polymerase chain reaction (PCR) so that up to 100 genetic targets may be analyzed. In the past multiplexing of digital PCR samples has been limited to only one probe per color. However multiple probes may be labeled by using combinatorial encoding of color, exploiting reaction rates of PCR cycles and modulating the intensity of Taqman and/or intercalating dyes therefore allowing a greater number of probes to be labeled.

Monoclonal Antibody against ATR-IP (Clone 11)

Mouse monoclonal antibody against the human ATR-interacting protein (ATR-IP). This antibody has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot.

Monoclonal Antibody Against CEP164 (Clone 13)

Mouse monoclonal antibody against the human centrosomal protein 164kDa (Cep164). This antibody binds to the phosphorylation site of Cep164 and has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot.

Monoclonal Antibody Against CEP164 (Clone 17)

Mouse monoclonal antibody against the human centrosomal protein 164kDa (Cep164). This antibody binds to the phosphorylation site of Cep164 and has been tested for use in immunoprecipitation and western blot.

Monoclonal Antibodies Against Chk2 (Clone 4B8)

Mouse monoclonal antibody (clone 4B8) against the human Serine/threonine-protein kinase Chk2. This antibody has been tested for use in immunoprecipitation and western blot.

Monoclonal Antibodies Against Mtpap (Clone 1D3)

Mouse monoclonal antibody against the human Poly (A) RNA polymerase, mitochondrial (mtPAP). This antibody has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot.

Inhibitory Antibodies From Synthetic Long CDR Libraries

Background: About 2M new cancer cases are diagnosed annually with a projected national economic burden of $160B by 2020. A means for better diagnostics and tailored therapies is needed to prevent cancer and detect it early. Even with early detection, effective therapies are limited and very expensive. Targeted therapies have been shifting towards monoclonal antibodies as an alternative to small molecule drugs due to their propensity for highly selective inhibition of enzymes involved in tumorigenesis. Brief Description: UCR Researchers have created synthetic antibodies by customizing a specific encoding region where antigen binding occurs. Antibody-antigen binding allows for activation and inhibition. Through their novel antibody design, they successfully inhibited protease enzymatic activity – with a very high hit rate of 65% for matrix metalloproteinase (MMP) – with high specificity and potency over traditional methods. Tumor-promoting MMP inhibition has never been accomplished due to difficulties in distinguishing them from tumor-suppressing MMP.

BrAD Seq: A simple, rapid and inexpensive method for constructing strand specific cDNA libraries for RNA-seq

Breath Adapter Directional sequencing (BrAD Seq) is a novel method for the production of strand specific RNA-seq libraries. The process reduces sample handling and requires far fewer enzymatic steps than current approaches while still producing high quality reads. The resulting technology is a quicker and cheaper way to generate RNA-seq libraries. Available for licensing are methods and compositions of matter for performing BrAD Seq.

Monoclonal Antibody Against mtPAP (Clone 3D2)

Mouse monoclonal antibody against the human Poly (A) RNA polymerase, mitochondrial (mtPAP). This antibody has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot. .

Monoclonal Antibody Against PNPase (Clone 3H5)

Mouse monoclonal antibody against the human mitochondrial polyribonucleotide nucleotidyltransferase 1 (PNPase). This antibody has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot.

Efficient Encoding Of Genomic Data Using Deduplication

Today, storage of genome sequence data relies heavily on compression, using techniques such as Lempil ziv and gziv, which is commonly stored in the .BAM or .SAM file format. Current techniques use standard reference genomes, such as HG19, compiled from a variety of human genomes (For example: http://genome.ucsc.edu/FAQ/FAQreleases.html). The results of many small reads are aligned and stored along with their quality data stores. The impact of whole genome sequencing, particularly in clinical treatment of cancer, will rapidly consume available storage. In 2010, 13M Americans had cancer. With existing technology, a single whole genome sequence for each person would be 39 exabyte’s (39,000 petabytes, 39 million terabytes or 39 billion gigabytes). There simply isn't a storage system that large; since storage capacity only grows at a rate of less than 20% per year. 

Generation of Metagenomic Next-generation Sequencing Libraries Optimal for Long-read Sequencing Technologies

This invention is a technology that prepares physical long-read fragments from short-read metagenomic libraries that can be sequenced quickly and efficiently using long-read next-generation sequencing technologies. As of this time, there are no existing commercially available technologies that can offer this advantage.

Alignment-Free Rapid Sequence Census Quantification (Kallisto)

Sequence census experiments utilize high-throughput sequencing to estimate abundance or copy count or copy number of each of one or more target sequences by comparing the DNA of a sequenced sample to its reference sequence. This aligning or mapping step consumes a considerable amount of computing power however.   UC Berkeley researchers have developed a software program (kallisto) for quantifying abundances of transcripts from RNA-Seq data, or more generally of target sequences using high-throughput sequencing reads based on pseudo-alignment for rapidly determining the compatibility of reads with targets, without the need for alignment. Pseudo-alignment of reads preserves the key information needed for quantification.   

Low-Cost Chromatin Assembly Kit

Brief description not available

Mobile Molecular Diagnostics System

There is a growing interest in point-of-care testing (POCT) where testing is done at or near the site of patient care, since POCT has a short therapeutic turnaround time, decreased process steps where errors can occur and only a small sample volume is required to perform a test.    UC Berkeley researchers have developed a mobile molecular diagnostics system that leverages efficient and dependable blood sampling, automated sample preparation, rapid optical detection of multi-analyte nucleic acids and proteins, and user-friendly systems integration with wireless communication.  The system includes a hand-held automated device with an adaptive sample control module, an optical signal transduction module, and an interface to a smartphone making this a reliable and field-applicable system for point-of-care and on-demand diagnostics. 

Bubble-Free Rapid Microfluidic PCR

Microfluidic-based polymerase chain reaction (PCR) methods have been widely used in research and diagnostics. Compared to standard PCR, microfluidic PCR reactions use less reagents, shorten analysis time, and can be integrated with other equipment.   Current methods, however, have major problems, including water evaporation, loss of reagents, and inconsistent optical pathlengths due to bubble generation. Moreover, the microfluidic devices used are challenging to fabricate.   To overcome the problems with conventional PCR and microfluidic PCR devices, UC Berkeley researchers have developed an efficient bubble-free microfluidic PCR device.  The device provides rapid cycling and a simple and reliable integrated fabrication system that is capable of being easily integrated with other standard equipment. 

Optical Cavity PCR

Outbreaks of infectious diseases especially require diagnostic tools that can be used at the point-of-care (POC). Polymerase chain reaction (PCR) is sensitive and allows accurate diagnoses, but developing simple and robust PCR methods that can be used at POC remains a challenge. In particular, slow thermal cycling capability and high power consumption continue to be barriers.  Researchers at UC Berkeley have developed optical cavity PCR to address these challenges. This technology allows ultrafast cycling with low power consumption, high amplification efficiency and a simple fabrication process, enabling its use as a POC device. 

High-Throughput Profiling of Point Mutations across the HIV-1 Genome

The Sun Group at UCLA has developed a quantitative, high-throughput assessment of the mutational susceptibility of genomic regions of HIV-1 to aid drug design.

System and Method for Fast Sequence Census Analysis

Massively Parallel Sequencing (MPS) approaches are attractive tools for sequencing. Typically, MPS methods can only obtain short read lengths (e.g., 50 to 250 base pairs), but generate many millions to billions of such short reads on the order of hours. Sequence census experiments utilize high-throughput sequencing to estimate abundance or copy count or copy number of each of one or more target sequences by comparing the DNA of a sequenced sample to its reference sequence. This step is called aligning or mapping the reads against the reference sequence. Aligning the read to the reference consumes a considerable amount of computing power. Thus, a major bottleneck in current methods for analysis of sequence census data is the requirement to align reads to reference.   UC Berkeley researchers have developed techniques for fast sequence census analysis that avoids the bottleneck of aligning a read with a reference sequence by inferring a non-alignment measure of compatibility; thus, improving accuracy or speed, or both, in comparison to previous methods. 

Novel isoforms of a regulator of the Hippo Pathway

This invention identifies two novel genetic spliced forms of a gene frequently involved in human cancer tissues, which could be developed as a biomarker for cancer and as a potential therapeutic target in the Hippo pathway.

A method for autocatalytic genome editing II

The CRISPR/CAS9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated genes) system has been found to be adaptable to nearly every organism studied including mammalian cells, fruit flies, and plants.  The broad adaptability of this system has lead in the past year to significant strides in refining the methodology and in the generation of many additional applications.  The innovation proposed is based solidly on existing technologies and should work in flies, mosquitos, human cells, and plants.

MicroRNA-214 as a Diagnostic and Prognostic Biomarker for Ulcerative Colitis and Colitis-Associated Colon Cancer Patients

Dr. Dimitrios Iliopoulos in UCLA Department of Medicine has identified a novel biomarker, microRNA-214 (miR-214), that predicts, at near 100% specificity, an ulcerative colitis patient’s risk for developing colon cancer.

Diagnostic, Prognostic and Therapeutic Uses of Non-Coding RNAs in Leukemia

The Rao group at UCLA has developed a method of using lincRNA expression levels as a diagnostic and prognostic tool for B acute lymphoblastic leukemia. Furthermore, regulation of certain leukemia-associated lincRNA may hold therapeutic potential.

HIGHLY SPECIFIC DIAGNOSTIC CLASSIFIERS OF ENDOMETRIOSIS

This invention provides a non-invasive method to detect endometriosis in women through the use of novel diagnostic biomarkers that detect the presence, absence, and/or severity of endometriosis.

  • Go to Page:

University of California
Innovation Alliances and Services

1111 Franklin Street, 5th Floor,Oakland,CA 94607-5200 |
http://www.ucop.edu/ott/
Tel: 510.587.6000 | Fax: 510.587.6090 | UC.technologies@ucop.edu